Thalidomide for Patients with β-Thalassemia: A Multicenter Experience

Area of Science:

• Hematology
• Pharmacology

Background:

• Beta-thalassemia is a serious inherited blood disorder requiring lifelong treatment.
• Conventional therapies like transfusions and chelation have limitations.
• Alternative therapeutic strategies are needed for beta-thalassemia management.

Purpose of the Study:

• To evaluate the efficacy and safety of thalidomide in patients with beta-thalassemia.
• To assess both short-term and long-term responses to thalidomide treatment.
• To identify factors influencing thalidomide's effectiveness in beta-thalassemia.

Main Methods:

• A multicenter trial involving patients with non-transfusion-dependent thalassemia (NTDT) and transfusion-dependent thalassemia (TDT).
• Patients received thalidomide therapy after failing conventional treatments.
• Efficacy was measured by hemoglobin levels, transfusion frequency, and fetal hemoglobin (HbF) production over 24 months.

Main Results:

• An overall response rate of 93.5% was observed, with significant increases in hemoglobin levels for NTDT patients.
• Transfusion requirements decreased significantly in TDT patients.
• Responses were sustained long-term, with minimal side effects reported, except for one case of peripheral neurotoxicity.

Conclusions:

• Thalidomide demonstrates significant therapeutic effects and sustained efficacy in patients with beta-thalassemia.
• Elevated baseline HbF levels independently predicted a positive response to thalidomide.
• Further research is needed to address potential complications like peripheral neuropathy before widespread clinical adoption.